-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 2, 2021, Acepodia announced the completion of a $109 million Series C financing
Acepodia is developing a pipeline of ACE therapies using its ACC technology to couple tumor-targeting antibodies to immune cells, such as natural killer (NK) cells or γδ T cells
▲Antibody-coupled cell technology (Image source: Acepodia's official website)
Its lead product, the potential "first-in-class" investigational therapy ACE1702, is an antibody-conjugated cell therapy generated by coupling a monoclonal antibody targeting HER2 to the surface of allogeneic NK cells
In addition, it is worth mentioning that WuXi Junuo has reached an agreement with Acepodia in 2020 to obtain exclusive priority authorization for the clinical and commercialization of ACE1702 in mainland China, Hong Kong and Macau
References:
[1] Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies.